Growth Metrics

Palvella Therapeutics (PVLA) Other Working Capital Changes (2016 - 2026)

Palvella Therapeutics has reported Other Working Capital Changes over the past 9 years, most recently at -$26.0 million for Q4 2022.

  • Quarterly Other Working Capital Changes fell 148.8% to -$26.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2022, down 93.06% year-over-year, with the annual reading at -$1.4 million for FY2025, 190.75% down from the prior year.
  • Other Working Capital Changes was -$26.0 million for Q4 2022 at Palvella Therapeutics, down from $451000.0 in the prior quarter.
  • Over five years, Other Working Capital Changes peaked at $53.3 million in Q4 2021 and troughed at -$47.4 million in Q4 2019.
  • The 5-year median for Other Working Capital Changes is $6.4 million (2019), against an average of -$344800.0.
  • Year-over-year, Other Working Capital Changes plummeted 739.54% in 2021 and then skyrocketed 905.36% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at $19.4 million in 2018, then plummeted by 344.46% to -$47.4 million in 2019, then surged by 70.27% to -$14.1 million in 2020, then soared by 478.94% to $53.3 million in 2021, then plummeted by 148.8% to -$26.0 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Other Working Capital Changes are -$26.0 million (Q4 2022), $451000.0 (Q3 2022), and $7.3 million (Q2 2022).